pocketful logo
Jubilant Pharmova Ltd logo

Jubilant Pharmova Ltd

NSE: JUBLPHARMA BSE: 530019

₹983.90

(-0.49)%

Wed, 04 Feb 2026, 07:11 am

mtf coin illustrationMTF 5x

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    15745.21

  • Net Profit

    836.30

  • P/B

    2.25

  • Sector P/E

    31.52

  • P/E

    16.80

  • EV/EBITDA

    9.91

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    22.44

  • ROCE (Industry)

    20.01

  • RONW (Industry)

    16.77

  • ROE

    9.50

  • ROCE

    8.39

  • Debt/Equity

    0.55

  • EPS (TTM)

    31.20

  • Dividend Yield

    0.50

  • Book Value

    413.79

  • Interest Cover

    3.58

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends paid are thoroughly covered by earnings (11.3x coverage).
  • Dividends after 3 years are expected to be thoroughly covered by earnings (15.5x coverage).
  • Dividends per share have been stable in the past 10 years.
  • Jubilant Life Sciences's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
thumbs up icon

Cons

  • Jubilant Life Sciences's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Cash flow for Jubilant Life Sciences is expected to increase but not above the 50% threshold in 2 years time.
  • Jubilant Life Sciences's earnings are expected to grow by 13.9% yearly, however this is not considered high growth (20% yearly).
  • Jubilant Life Sciences's earnings growth is positive but not above the India market average.
  • Jubilant Life Sciences's net income is expected to increase but not above the 50% threshold in 2 years time.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters47.6847.6847.6850.6850.68
FII15.9616.5717.4017.2216.96
DII11.2210.529.537.056.98
Public25.1425.2325.3925.0625.39
Government00000

Read More

Technical Analysis

RSI

45.72

MACD

-24.30

50 DMA

1043.61

200 DMA

1081.47

Support and Resistance

TypeR1R2R3PPS1S2S3
Classic1367.331186.431084.171005.53903.27824.63643.73
Fibonacci1186.431117.331074.641005.53936.43893.74824.63
Camarilla1031.651015.06998.481005.53965.32948.74932.15

Pivots Level: Classic

R3

+361.80

1367.33

R2

+180.90

1186.43

R1

+78.63

1084.17

1005.53
1005.53
Pivot Point
LTP: 983.90

S1

-102.27

903.27

S2

-180.90

824.63

S3

-361.80

643.73

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    976.08

  • 20-EMA

    993.16

  • 30-EMA

    1009.24

  • 50-EMA

    1031.92

  • 100-EMA

    1057.39

  • 200-EMA

    1055.25

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
31 Oct 2025board-meetingsQuarterly Results
06 Aug 2025agm
16 May 2025dividend₹5.00 Dividend /Share25 Jul 2025
09 Aug 2024agm
29 May 2024dividend₹5.00 Dividend /Share02 Aug 2024
07 Aug 2023agm
29 May 2023dividend₹5.00 Dividend /Share10 Aug 2023
05 Sept 2022agm
27 May 2022dividend₹5.00 Dividend /Share12 Aug 2022
10 Dec 2021egm

Read More

Peer Comparison

Jubilant Pharmova Ltd logo

Jubilant Pharmova Ltd

Cipla Ltd logo

Cipla Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Read More

About Jubilant Pharmova Ltd

Jubilant Pharmova in radiopharma, allergy immunotherapy, contract development and manufacturing of sterile injectable, generics, contract research development and manufacturing and proprietary novel drugs businesses.

Industry

Pharmaceuticals - Indian - Bulk Drugs

Founded

1978

Headquarters

CEO

Shyam S Bhartia

Employees

Contact

Website icon

Website

http://www.jubl.com

Email icon

Email

investors@jubl.com

Phone icon

Phone

91-5924-267200

Location icon

Location

Bhartiagram Gajraula, , Amroha, Uttar Pradesh, 244223

Read More

jubilant pharmova ltd History

YearHistory
2019
  • Celebrated decade of Social Entrepreneur of the Year India Awards partnership.
2020
  • Supported COVID-19 efforts with health/safety materials in Karnataka and free hand sanitizers.
  • Launched JUBI-R (remdesivir) in India for COVID-19 treatment.
  • Hindustan Times Fellowship Seed Transformation Program with Schwab Foundation.
2021
  • Company name changed to Jubilant Pharmova Ltd.
  • Undertaking of Jubilant Generics Limited.
2022
  • Jubilant HollisterStier announced CAD 100 Mn expansion of CMO facility in Montreal, Canada.
  • Jubilant HollisterStier entered $149.6 Mn cooperative agreement with US Government for vaccine manufacturing capacity expansion.
  • Presented data on Isoform Selective PAD4 inhibitors at AACR Meeting.
  • Received FDA clearance of IND for JBI-802, a dual LSD1 and HDAC6 inhibitor for solid tumors.
2023
  • Received additional funding from Government of Canada for Montreal facility expansion.
  • Radiopharma business received USFDA approval for Technetium Tc-99m Mertiatide injection.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
KOTAK FUNDS - INDIA MIDCAP FUNDBuy1593500106013 Jun 2025
KOTAK MAHINDRA MUTUAL FUNDBuy1693434106013 Jun 2025
NIKITA RESOURCES PRIVATE LIMITEDSell19624341060.3713 Jun 2025
JUBILANT ENPRO PRIVATE LIMITEDSell2116000106013 Jun 2025
GRAVITON RESEARCH CAPITAL LLPBuy8252891157.7213 Sept 2024
GRAVITON RESEARCH CAPITAL LLPSell8252891158.1813 Sept 2024
EAST BRIDGE CAPITAL MASTER FUND I LTDBuy140500085105 Aug 2024
EAST BRIDGE CAPITAL MASTER FUND LIMITEDSell140500085105 Aug 2024
GRAVITON RESEARCH CAPITAL LLPBuy971936842.0301 Aug 2024
GRAVITON RESEARCH CAPITAL LLPSell971936842.4701 Aug 2024

Read More

jubilant pharmova limited News

Jubilant Pharmova schedules investor meets for Feb 9

Jubilant Pharmova announces physical investor/analyst meetings on February 09, 2026 in Mumbai to discuss Q3FY26 earnings with 29 institutional investors at Nuvama India Conference 2026.

02 Feb 2026

co actions results

Jubilant Pharmova faces ₹22.10 cr tax demand

Jubilant Pharmova received Income Tax Department order raising ₹22.10 crores tax demand for FY2020, citing arithmetical errors and transfer pricing adjustments. Company plans rectification appeal.

31 Dec 2025

stocks

Jubilant Pharmova invests in Canadian subsidiary

Jubilant Pharmova Limited announces CAD 30,000 investment in Jubilant Pharmaceuticals Inc., Canada, making it a step-down wholly owned subsidiary to establish branded generic business in the Canadian market.

30 Dec 2025

co actions results

Jubilant Pharmova Subsidiary Faces ₹1.73 Cr GST Demand

Jubilant Generics Limited receives GST demand order of ₹1.57 crores plus ₹15.68 lakh penalty from Roorkee GST authorities for erroneously sanctioned refund. Company plans appeal.

27 Dec 2025

stocks

Jubilant Pharmova's Subsidiary Receives GST Demand Order Worth Rs 13.77 Crore

Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Pharmova, received an adjudication order from Deputy Commissioner of Commercial Taxes, Mysuru, demanding GST, interest and penalty totaling Rs 13.77 crore for Financial Year 2021-2022 related to Input Tax Credit issues. The company plans to file a detailed appeal contesting the order and expects no financial or operational impact.

05 Dec 2025

stock

Showing 1–5 of 43
Rows per page:

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800